CHICAGO, Jan. 26, 2016 -- The Female Health Company (NASDAQ:FHCO) today announced that it will host an investor conference call to discuss its operating results for the first quarter of FY2016 on Tuesday, February 2, 2016 at 11:15 a.m. Eastern Time (ET). The Company expects to report its operating results earlier the same day.
Shareholders and other interested parties may participate in the conference call by dialing 1-844-868-9326 (international participants dial 1-412-317-6594) and asking to be connected to "The Female Health Company Conference Call" a few minutes before 11:15 a.m. ET.
A replay of the conference call will be available one hour after the call through 9:00 a.m. ET on Tuesday, February 9, 2016, by dialing 1-877-344-7529 (international callers dial 1-412-317-0088) and entering the conference ID # 10079795. After Tuesday, February 9, 2016, the replay of the call will be available on the Company’s website at www.fhcinvestor.com.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, the product has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
“Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.
For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to [email protected].
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123


Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 



